8-K
filed June 5, 2023, 7:59 PM ET
ticker CVSI
CIK 0001510964
other material
confidence high
sentiment neutral
materiality 0.40
CV Sciences shareholders approve 2023 Equity Incentive Plan, elect directors
CV Sciences, Inc.
- Stockholders approved 2023 Equity Incentive Plan (11.7M for, 8.6M against) to replace 2013 Plan.
- Elected directors: Dr. Jamie Corroon, Joseph Dowling, Bill McCorkle to serve until next annual meeting.
- Ratified Haskell & White LLP as independent auditor for FY2023 (74.7M for, 1.2M against).
- Non-binding advisory vote on named executive officer compensation approved (11.8M for, 8.7M against).
- Quorum of 50.4% (76.6M of 152.1M shares) present at virtual annual meeting on June 1, 2023.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CV Sciences, Inc. shareholders approved Proposal 3 - Adoption of our 2023 Plan at the 2023-06-01 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CV Sciences, Inc. shareholders approved Proposal 1 - Election of Directors at the 2023-06-01 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CV Sciences, Inc. shareholders approved Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CV Sciences, Inc. shareholders approved Proposal 4 - Advisory Vote to Approve Named Executive Officer Compensation at the 2023-06-01 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-01
Exact text from the filing
On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.